Yep, we have the open arm trial participants who did very well according to past company presentations. Like really well. There's no sugar coating the speedy terminal nature of GBM. People have eyes and ears, and investigators at the highest levels of their field have tradecraft awareness to recognize the directional trend line to support or not support the underlying treatment hypothesis under investigation.
Market Data 
Markets 
AI
